货号: 4444415
High specificity and rapid time-to-results
The ViralSEQ MMV assay detects the four known strains of MMV: i, p, m, and c, including seven genomic sequences reported in the NCBI database. Table 1 shows the specificity of the ViralSEQ MMV assay and lack of cross-reactivity with unrelated DNA. The assay workflow is simple and delivers results in just under 4 hours (Figure 1).
Streamlined process for surveillance and early detection
The ViralSEQ MMV Detection Assay is part of the Cell Culture Rapid Methods Program, designed to streamline the detection of three common contaminants of mammalian cell culture-based biopharmaceutical manufacturing (Figure 2). The program sets new workflow standards in efficiency and product quality, combining one sample preparation step with real-time PCR-based assays for the detection of mycoplasma, vesivirus, and MMV on one instrument platform.
Reliable results
The ViralSEQ MMV Detection Assay includes an MMV Discriminatory Positive/Extraction Control, which is a plasmid DNA containing the MMV DNA sequence that is recognized by the MMV detection assay (FAM probe). This control (Figure 3) was designed to behave like MMV DNA in both the sample preparation and detection portions of the process. In addition, the control was engineered with an additional VIC probe binding sequence. The presence of both FAM and VIC signal in a PCR reaction can be used to discriminate a positive test result between MMV (FAM) and the control DNA (FAM and VIC). This novel control enables risk-free DNA spike control testing, eliminating the possibility of a false positive test result due to accidental cross-contamination of a test sample with the positive control DNA.